When will there be a generic for nurtec?

Short answer: there isn’t a generic Nurtec (rimegepant) available yet. The timing of any generic depends on patent protections and regulatory exclusivities, which can push generic entry out by several years.

What we know in general:
- Nurtec ODT contains rimegepant. It would be the subject of patent protections (composition-of-matter and other patents) plus any data exclusivity from FDA.
- In the U.S., there is also a 5-year data exclusivity period tied to the first approval of a new chemical entity, which can delay generic entry. That period typically ends around the mid-2020s, but other patents can extend protection beyond that.
- Because of additional patents and potential litigation, a generic could be delayed well past the initial exclusivity window.

What you can check to get a precise answer:
- FDA Orange Book entry for rimegepant (Nurtec): shows active patents and their expiration dates, plus any data exclusivity.
- Biohaven’s disclosures or investor materials for patent coverage and expected timelines.
- If you’re outside the U.S., check your country’s regulatory database for patent and exclusivity status.

If you’d like, tell me your country and I can guide you to the current Orange Book (or equivalent) status and any recent updates. I can’t browse in real time, but I can explain how to interpret the latest listings and what dates to look for.